JOP20140049B1 - أجسام مضادة ترتبط بـ il-23 - Google Patents
أجسام مضادة ترتبط بـ il-23Info
- Publication number
- JOP20140049B1 JOP20140049B1 JOP/2014/0049A JOP20140049A JOP20140049B1 JO P20140049 B1 JOP20140049 B1 JO P20140049B1 JO P20140049 A JOP20140049 A JO P20140049A JO P20140049 B1 JOP20140049 B1 JO P20140049B1
- Authority
- JO
- Jordan
- Prior art keywords
- antibody
- useful
- treatment
- antibodies
- bind
- Prior art date
Links
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
يتعلق الاختراع الحالي بجسم مضاد يرتبط بالوحدة الفرعية p19 من IL-23 البشري ويتم تمييزه بأنه يكون بألفة عالية، وله خواص انتقائية وتعادل. يفيد الجسم المضاد في علاج أو الوقاية من حالة التهابية أو متعلقة بالمناعة الذاتية منتقاة من المجموعة المؤلفة من المؤلفة من التصلب المتعدد، التهاب المفاصل الروماتويدي، الصدفية، أمراض التهاب الأمعاء، التهاب الفقرات الروماتويدي، المرض المتعلق برفض العائل للجزء المزروع، الذئبة والمتلازمة الأيضية. كما يفيد الجسم المضاد في علاج السرطان.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361774732P | 2013-03-08 | 2013-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20140049B1 true JOP20140049B1 (ar) | 2021-08-17 |
Family
ID=51488096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2014/0049A JOP20140049B1 (ar) | 2013-03-08 | 2014-02-25 | أجسام مضادة ترتبط بـ il-23 |
Country Status (41)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| CN108135983A (zh) * | 2015-10-30 | 2018-06-08 | 伊莱利利公司 | 抗cgrp /抗il-23双特异性抗体及其用途 |
| TW201902926A (zh) | 2017-05-03 | 2019-01-16 | 美商美國禮來大藥廠 | 抗cgrp／抗il-23雙特異性抗體及其用途 |
| TWI837532B (zh) | 2018-03-30 | 2024-04-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| TWI725532B (zh) | 2018-09-11 | 2021-04-21 | 美商美國禮來大藥廠 | 治療牛皮癬之方法 |
| TWI850365B (zh) | 2019-04-22 | 2024-08-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
| MX2022004311A (es) | 2019-10-15 | 2022-05-10 | Lilly Co Eli | Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. |
| KR20220143005A (ko) | 2019-12-20 | 2022-10-24 | 노바록 바이오테라퓨틱스 리미티드 | 항-인터루킨-23 p19 항체 및 이의 사용 방법 |
| CN111718414B (zh) * | 2020-06-12 | 2021-03-02 | 江苏荃信生物医药有限公司 | 抗人白介素23单克隆抗体及其应用 |
| WO2022041390A1 (zh) * | 2020-08-28 | 2022-03-03 | 江苏荃信生物医药股份有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法 |
| TW202428304A (zh) | 2020-09-10 | 2024-07-16 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
| US20240254217A1 (en) | 2021-05-28 | 2024-08-01 | Eli Lilly And Company | Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis |
| CN113698480B (zh) * | 2021-09-18 | 2022-07-01 | 东大生物技术(苏州)有限公司 | 一组il-23单克隆抗体及其医药用途 |
| EP4409298A1 (en) | 2021-09-30 | 2024-08-07 | Eli Lilly and Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
| WO2024178157A1 (en) | 2023-02-22 | 2024-08-29 | Eli Lilly And Company | Regulation of genes in ulcerative colitis and the uses thereof |
| WO2024191771A1 (en) | 2023-03-10 | 2024-09-19 | Eli Lilly And Company | Methods of treating ulcerative colitis |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| CA2518262C (en) | 2003-03-10 | 2014-05-06 | Schering Corporation | Uses of il-23 agonists and antagonists; related reagents |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| CN101252951B (zh) * | 2005-06-30 | 2011-12-21 | 森托科尔公司 | 抗il-23抗体、组合物、方法和用途 |
| CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
| ES2347690T3 (es) * | 2005-08-25 | 2010-11-03 | Eli Lilly And Company | Anticuerpos anti-il-23. |
| CA2620802A1 (en) * | 2005-08-31 | 2007-03-08 | Schering Corporation | Engineered anti-il-23 antibodies |
| ES2517420T3 (es) * | 2005-12-29 | 2014-11-03 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos |
| PL2059534T3 (pl) | 2007-02-23 | 2012-09-28 | Merck Sharp & Dohme | Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej |
| US20100111966A1 (en) * | 2007-02-23 | 2010-05-06 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| WO2008115732A2 (en) | 2007-03-20 | 2008-09-25 | Eli Lilly And Company | Anti-sclerostin antibodies |
| JP5290276B2 (ja) * | 2007-05-08 | 2013-09-18 | ジェネンテック， インコーポレイテッド | システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体 |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| EP2435480A1 (en) * | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| PE20141162A1 (es) * | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| KR101992502B1 (ko) * | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법 |
-
2014
- 2014-02-25 AR ARP140100582A patent/AR094877A1/es active IP Right Grant
- 2014-02-25 TW TW103106335A patent/TWI636063B/zh active
- 2014-02-25 JO JOP/2014/0049A patent/JOP20140049B1/ar active
- 2014-03-04 LT LTEP14761062.0T patent/LT2964258T/lt unknown
- 2014-03-04 PT PT147610620T patent/PT2964258T/pt unknown
- 2014-03-04 MY MYPI2015702927A patent/MY171226A/en unknown
- 2014-03-04 KR KR1020157024032A patent/KR101775115B1/ko active Active
- 2014-03-04 US US14/195,889 patent/US9023358B2/en active Active
- 2014-03-04 SG SG11201507176VA patent/SG11201507176VA/en unknown
- 2014-03-04 EP EP14761062.0A patent/EP2964258B1/en active Active
- 2014-03-04 MA MA38382A patent/MA38382A1/fr unknown
- 2014-03-04 PE PE2015001903A patent/PE20151529A1/es active IP Right Grant
- 2014-03-04 DK DK14761062.0T patent/DK2964258T3/da active
- 2014-03-04 AP AP2015008708A patent/AP2015008708A0/xx unknown
- 2014-03-04 SI SI201431653T patent/SI2964258T1/sl unknown
- 2014-03-04 RS RS20201236A patent/RS60928B1/sr unknown
- 2014-03-04 KR KR1020177024414A patent/KR20170103037A/ko not_active Ceased
- 2014-03-04 ES ES14761062T patent/ES2822662T3/es active Active
- 2014-03-04 PH PH1/2015/501994A patent/PH12015501994B1/en unknown
- 2014-03-04 EP EP23207282.7A patent/EP4311558A3/en active Pending
- 2014-03-04 PL PL14761062T patent/PL2964258T3/pl unknown
- 2014-03-04 WO PCT/US2014/020064 patent/WO2014137962A1/en active Application Filing
- 2014-03-04 EA EA201591368A patent/EA031524B1/ru not_active IP Right Cessation
- 2014-03-04 CA CA2901462A patent/CA2901462C/en active Active
- 2014-03-04 CN CN201480012747.7A patent/CN105307681B/zh active Active
- 2014-03-04 UA UAA201508670A patent/UA123198C2/uk unknown
- 2014-03-04 HU HUE14761062A patent/HUE051357T2/hu unknown
- 2014-03-04 JP JP2015561515A patent/JP6096938B2/ja active Active
- 2014-03-04 MX MX2015011959A patent/MX370396B/es active IP Right Grant
- 2014-03-04 EP EP20193400.7A patent/EP3789037A1/en not_active Withdrawn
- 2014-03-04 BR BR112015019611-0A patent/BR112015019611B1/pt active IP Right Grant
- 2014-03-04 AU AU2014226094A patent/AU2014226094C1/en active Active
-
2015
- 2015-05-01 US US14/702,124 patent/US9688753B2/en active Active
- 2015-07-22 ZA ZA2015/05285A patent/ZA201505285B/en unknown
- 2015-08-12 TN TN2015000348A patent/TN2015000348A1/en unknown
- 2015-08-20 IL IL240731A patent/IL240731B/en active IP Right Grant
- 2015-08-26 CL CL2015002388A patent/CL2015002388A1/es unknown
- 2015-09-08 EC ECIEPI201538626A patent/ECSP15038626A/es unknown
-
2016
- 2016-01-14 HK HK16100387.3A patent/HK1212252A1/xx unknown
-
2017
- 2017-06-01 US US15/611,008 patent/US20170275356A1/en not_active Abandoned
-
2020
- 2020-01-14 IL IL272042A patent/IL272042B/en unknown
- 2020-10-09 HR HRP20201633TT patent/HRP20201633T1/hr unknown
- 2020-11-16 CY CY20201101081T patent/CY1123589T1/el unknown
-
2023
- 2023-10-03 FI FIC20230030C patent/FIC20230030I1/fi unknown
- 2023-10-04 NO NO2023037C patent/NO2023037I1/no unknown
- 2023-10-06 NL NL301247C patent/NL301247I2/nl unknown
- 2023-10-06 CY CY2023021C patent/CY2023021I2/el unknown
- 2023-10-13 FR FR23C1036C patent/FR23C1036I2/fr active Active
- 2023-10-18 HU HUS2300036C patent/HUS2300036I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20140049B1 (ar) | أجسام مضادة ترتبط بـ il-23 | |
| JO3532B1 (ar) | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها | |
| EA201591478A1 (ru) | Биспецифические антитела против фно и ил-17 | |
| GEP201706794B (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
| NZ723858A (en) | Anti-human ox40l antibodies, uses & methods | |
| EA201491622A1 (ru) | Биспецифические антитела против baff и ил-17 | |
| NZ733462A (en) | Antibodies to tau and uses thereof | |
| MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
| EA201300418A1 (ru) | Антитела к человеческому tweak и варианты их применения | |
| EA201691521A1 (ru) | Антитела к интерлейкину-21 | |
| TN2015000377A1 (en) | Pan-elr+ cxc chemokine antibodes | |
| MX2021010472A (es) | Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. | |
| MX2015015232A (es) | Anticuerpo monoclonal dirigido contra cxcr5. | |
| JP2017532332A5 (ar) | ||
| MX2019006676A (es) | Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia. | |
| TN2014000413A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
| TH1401006266A (th) | แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี | |
| TH169590A (th) | แอนติบอดีที่ยึดเกาะ il-23 |